Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer

A comparative review

Girolamo Ranieri, Marianna Pantaleo, Mariagrazia Piccinno, Maria Roncetti, Maddalena Mutinati, Ilaria Marech, Rosa Patruno, Annalisa Rizzo, Raffaele Luigi Sciorsci

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Tyrosine kinase receptors (TKRs) play a key role in tumour cell proliferation and survival since they are involved in endothelial cell activation leading to tumour neoangiogenesis. In particular, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are overexpressed or constitutively activated in human and pet malignancies. A variety of small molecule inhibitors targeting specific tyrosine kinases (known as tyrosine kinase inhibitors or TKIs) have recently been approved, or are under investigation, for the treatment of human cancer. TKI application in animal cancer is however relatively recent. This review aims to illustrate the major aspects of tyrosine kinase dysfunctions, with special regard to human and animal cancer of the mammary gland, providing an update on the background of the anti-angiogenic and anti-neoplastic properties of TKIs in human and veterinary cancer.

Original languageEnglish
Pages (from-to)293-308
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume88
Issue number2
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Pets
Protein-Tyrosine Kinases
Breast Neoplasms
Neoplasms
Proto-Oncogene Proteins c-kit
Platelet-Derived Growth Factor Receptors
Animal Mammary Glands
Vascular Endothelial Growth Factor Receptor
Macrophage Colony-Stimulating Factor
Receptor Protein-Tyrosine Kinases
Cell Survival
Endothelial Cells
Cell Proliferation

Keywords

  • Angiogenesis
  • Bitch
  • Breast cancer
  • Comparative oncology
  • Pets
  • Queen
  • Tyrosine kinase inhibitors
  • Tyrosine kinase receptors
  • Women

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer : A comparative review. / Ranieri, Girolamo; Pantaleo, Marianna; Piccinno, Mariagrazia; Roncetti, Maria; Mutinati, Maddalena; Marech, Ilaria; Patruno, Rosa; Rizzo, Annalisa; Sciorsci, Raffaele Luigi.

In: Critical Reviews in Oncology/Hematology, Vol. 88, No. 2, 11.2013, p. 293-308.

Research output: Contribution to journalArticle

Ranieri, Girolamo ; Pantaleo, Marianna ; Piccinno, Mariagrazia ; Roncetti, Maria ; Mutinati, Maddalena ; Marech, Ilaria ; Patruno, Rosa ; Rizzo, Annalisa ; Sciorsci, Raffaele Luigi. / Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer : A comparative review. In: Critical Reviews in Oncology/Hematology. 2013 ; Vol. 88, No. 2. pp. 293-308.
@article{978a1e951d694138b222195595bbb306,
title = "Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative review",
abstract = "Tyrosine kinase receptors (TKRs) play a key role in tumour cell proliferation and survival since they are involved in endothelial cell activation leading to tumour neoangiogenesis. In particular, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are overexpressed or constitutively activated in human and pet malignancies. A variety of small molecule inhibitors targeting specific tyrosine kinases (known as tyrosine kinase inhibitors or TKIs) have recently been approved, or are under investigation, for the treatment of human cancer. TKI application in animal cancer is however relatively recent. This review aims to illustrate the major aspects of tyrosine kinase dysfunctions, with special regard to human and animal cancer of the mammary gland, providing an update on the background of the anti-angiogenic and anti-neoplastic properties of TKIs in human and veterinary cancer.",
keywords = "Angiogenesis, Bitch, Breast cancer, Comparative oncology, Pets, Queen, Tyrosine kinase inhibitors, Tyrosine kinase receptors, Women",
author = "Girolamo Ranieri and Marianna Pantaleo and Mariagrazia Piccinno and Maria Roncetti and Maddalena Mutinati and Ilaria Marech and Rosa Patruno and Annalisa Rizzo and Sciorsci, {Raffaele Luigi}",
year = "2013",
month = "11",
doi = "10.1016/j.critrevonc.2013.05.009",
language = "English",
volume = "88",
pages = "293--308",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer

T2 - A comparative review

AU - Ranieri, Girolamo

AU - Pantaleo, Marianna

AU - Piccinno, Mariagrazia

AU - Roncetti, Maria

AU - Mutinati, Maddalena

AU - Marech, Ilaria

AU - Patruno, Rosa

AU - Rizzo, Annalisa

AU - Sciorsci, Raffaele Luigi

PY - 2013/11

Y1 - 2013/11

N2 - Tyrosine kinase receptors (TKRs) play a key role in tumour cell proliferation and survival since they are involved in endothelial cell activation leading to tumour neoangiogenesis. In particular, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are overexpressed or constitutively activated in human and pet malignancies. A variety of small molecule inhibitors targeting specific tyrosine kinases (known as tyrosine kinase inhibitors or TKIs) have recently been approved, or are under investigation, for the treatment of human cancer. TKI application in animal cancer is however relatively recent. This review aims to illustrate the major aspects of tyrosine kinase dysfunctions, with special regard to human and animal cancer of the mammary gland, providing an update on the background of the anti-angiogenic and anti-neoplastic properties of TKIs in human and veterinary cancer.

AB - Tyrosine kinase receptors (TKRs) play a key role in tumour cell proliferation and survival since they are involved in endothelial cell activation leading to tumour neoangiogenesis. In particular, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are overexpressed or constitutively activated in human and pet malignancies. A variety of small molecule inhibitors targeting specific tyrosine kinases (known as tyrosine kinase inhibitors or TKIs) have recently been approved, or are under investigation, for the treatment of human cancer. TKI application in animal cancer is however relatively recent. This review aims to illustrate the major aspects of tyrosine kinase dysfunctions, with special regard to human and animal cancer of the mammary gland, providing an update on the background of the anti-angiogenic and anti-neoplastic properties of TKIs in human and veterinary cancer.

KW - Angiogenesis

KW - Bitch

KW - Breast cancer

KW - Comparative oncology

KW - Pets

KW - Queen

KW - Tyrosine kinase inhibitors

KW - Tyrosine kinase receptors

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=84885834050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885834050&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2013.05.009

DO - 10.1016/j.critrevonc.2013.05.009

M3 - Article

VL - 88

SP - 293

EP - 308

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -